Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · November 26, 2022

Metabolic Effects of Sotagliflozin on Blood Pressure and Body Weight Reduction in People With Diabetes

Journal of Diabetes and its Complications


Additional Info

Journal of Diabetes and its Complications
Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials
J Diabetes Complicat 2022 Nov 04;36(12)108352, J Wu, X Zhao, H Chen, S Zhu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading